PDS Biotechnology CorporationPDSBNASDAQ
LOADING
|||
Year-over-year research & development expense growth
| Period | Value |
|---|---|
| Q3 2025 | 8.63% |
| Q2 2025 | -27.75% |
| Q1 2025 | 28.73% |
| Q4 2024 | -33.42% |
| Q3 2024 | 50.27% |
| Q2 2024 | -32.46% |
| Q1 2024 | -10.20% |
| Q4 2023 | 15.77% |
| Q3 2023 | -19.44% |
| Q2 2023 | 36.98% |
| Q1 2023 | -63.83% |
| Q4 2022 | 271.13% |
| Q3 2022 | 15.72% |
| Q2 2022 | -27.12% |
| Q1 2022 | 52.28% |
| Q4 2021 | -8.10% |
| Q3 2021 | 33.42% |
| Q2 2021 | 95.62% |
| Q1 2021 | -42.97% |
| Q4 2020 | 20.23% |
| Q3 2020 | 45.72% |
| Q2 2020 | -28.27% |
| Q1 2020 | 46.24% |
| Q4 2019 | -26.48% |
| Q3 2019 | -2.81% |
| Q2 2019 | 83.20% |
| Q1 2019 | 112.28% |
| Q4 2018 | 150.02% |
| Q3 2018 | -92.31% |
| Q2 2018 | -80.19% |
| Q1 2018 | 17.61% |
| Q4 2017 | 56.72% |
| Q3 2017 | -22.97% |
| Q2 2017 | 18.26% |
| Q1 2017 | 11.95% |
| Q4 2016 | 0.80% |
| Q3 2016 | 12.55% |
| Q2 2016 | 11.74% |
| Q1 2016 | 1.56% |
| Q4 2015 | -19.10% |